Suppr
超能文献

Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children.

作者信息

Nagasawa Masayuki, Mitsuiki Noriko, Ono Toshiaki, Takagi Masatoshi, Oda Hiromi, Yasuhara Masato, Mizutani Shuki

出版信息

Int J Hematol. 2010 May;91(4):728-30. doi: 10.1007/s12185-010-0572-2. Epub 2010 Apr 27.

DOI:10.1007/s12185-010-0572-2

PMID:20422470

Abstract

摘要

相似文献

Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children.

Int J Hematol. 2010 May;91(4):728-30. doi: 10.1007/s12185-010-0572-2. Epub 2010 Apr 27.

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.

Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98. doi: 10.1016/j.bbmt.2007.09.015.

Busulfan in children: impact of development on dose-exposure-response relationship?

Pediatr Blood Cancer. 2010 Feb;54(2):191-2. doi: 10.1002/pbc.22296.

The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.

Ann Transplant. 2014 May 9;19:214-24. doi: 10.12659/AOT.889933.

Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.

Am J Hematol. 2017 Jul;92(7):607-613. doi: 10.1002/ajh.24734. Epub 2017 May 30.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.

Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.

Mil Med. 2006 Feb;171(2):161-5. doi: 10.7205/milmed.171.2.161.

Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.

Bone Marrow Transplant. 2010 Mar;45(3):602-4. doi: 10.1038/bmt.2009.195. Epub 2009 Aug 17.

New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.

Pediatr Blood Cancer. 2015 Apr;62(4):680-6. doi: 10.1002/pbc.25376. Epub 2014 Dec 31.

Pharmacokinetic analysis for model-supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients.

Pediatr Transplant. 2020 Jun;24(4):e13696. doi: 10.1111/petr.13696. Epub 2020 Mar 20.

引用本文的文献

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Int J Hematol. 2015 Nov;102(5):611-6. doi: 10.1007/s12185-015-1853-6. Epub 2015 Aug 5.

Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.

Bone Marrow Transplant. 2014 Mar;49(3):366-9. doi: 10.1038/bmt.2013.188. Epub 2013 Dec 9.

本文引用的文献

Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.

Bone Marrow Transplant. 2010 Mar;45(3):602-4. doi: 10.1038/bmt.2009.195. Epub 2009 Aug 17.

Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.

J Clin Pharmacol. 2008 Sep;48(9):1052-62. doi: 10.1177/0091270008321940. Epub 2008 Jul 17.

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.

Cancer Chemother Pharmacol. 2008 Jan;61(1):113-23. doi: 10.1007/s00280-007-0455-2. Epub 2007 Mar 29.

Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14. doi: 10.1016/j.bbmt.2006.10.026.

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Blood. 2004 Dec 1;104(12):3507-12. doi: 10.1182/blood-2004-04-1389. Epub 2004 Aug 17.

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

Bone Marrow Transplant. 2001 Oct;28(8):743-51. doi: 10.1038/sj.bmt.1703207.

Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.

Bone Marrow Transplant. 2001 Dec;28(11):1013-8. doi: 10.1038/sj.bmt.1703264.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译